Biotech and Pharmaceuticals
CDC advisers recommend spring Covid boosters for older adults
A pharmacist delivers a COVID-19 booster dose at a Chicago CVS store. Antonio Perez | Tribune News Service | Getty Images People at higher risk for the most severe complications of Covid — primarily those ages 65 and older — should receive a booster shot this spring, advisers to the Centers for Disease Control and Prevention […]
Read More
Novavax misses quarterly estimates, but vaccine maker narrows losses as it slashes costs
Budrul Chukrut | Lightrocket | Getty Images Vaccine maker Novavax on Wednesday reported fourth-quarter revenue and earnings that missed Wall Street’s estimates and reiterated plans to cut costs as it fights to stay afloat. Still, Novavax narrowed its losses in the quarter from the same period a year ago, even as demand for the biotech […]
Read More
Viking stock doubled Tuesday. In this article's the place the following moves in the weight problems room could arrive from
Anti-weight problems drugmakers Novo Nordisk and Eli Lilly have a big lead on their competitiveness, but supplied the large and beneficial marketplace, rivals are nevertheless keen to sign up for the race. Bank of America analyst Geoff Meacham has been quite bullish about the option, which he phone calls “unparalleled” offered the prevalence of obesity […]
Read More
Healthy Returns: The newest treatment use for weight loss drugs? Liver disease
Image of a healthy liver not ravaged by fatty liver disease. BSIP | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! Drugmakers aren’t just racing to develop drugs that treat obesity. They’re also competing to expand the uses of those weight loss treatments, including […]
Read More
Viking Therapeutics stock jumps 80% after positive weight loss drug trial results
Cr | Istock | Getty Images Shares of Viking Therapeutics soared more than 80% in premarket trading Tuesday after the company’s experimental weight loss drug showed promising initial results in a mid-stage trial. Viking Therapeutics is one of several small obesity drugmakers hoping to enter the budding weight loss drug industry, which analysts say could […]
Read More
The 11 GRANOLAS shares power Europe to file highs, drawing Magnificent Seven comparisons
The German share selling price index DAX graph is pictured at the inventory trade in Frankfurt, Germany, January 19, 2024. Employees | Reuters Above the last 12 months, just 11 shares manufactured up half of the gains that driven the pan-European Stoxx 600 stock index to a document-large close on Friday. Earlier this month, Goldman […]
Read More
The 11 GRANOLAS stocks power Europe to record highs, drawing Magnificent Seven comparisons
The German share price index DAX graph is pictured at the stock exchange in Frankfurt, Germany, January 19, 2024. Staff | Reuters Over the last 12 months, just 11 stocks made up half of the gains that powered the pan-European Stoxx 600 stock index to a record-high close on Friday. Earlier this month, Goldman Sachs […]
Read More
Novavax to settle dispute over canceled Covid vaccine purchase agreement
A health worker prepares a dose of the Novavax vaccine as the Dutch Health Service Organization starts with the Novavax vaccination program on March 21, 2022 in The Hague, Netherlands. Patrick Van Katwijk | Getty Images Novavax on Thursday said it will settle a bitter arbitration dispute with Gavi, a nongovernmental global vaccine organization, over a […]
Read More
Moderna posts surprise quarterly profit even as Covid vaccines sales plummet
Nikos Pekiaridis | Nurphoto | Getty Images Moderna on Thursday posted a surprise quarterly profit, in part boosted by deferred revenue, even as the company saw slumping sales from its Covid vaccine, its only marketable product. The results cap a rocky year for the biotech company and other Covid vaccine makers, which all saw revenue plunge […]
Read More
Healthy Returns: The launch of breakthrough Alzheimer’s drug Leqembi is off to a slow start
Good afternoon! The launch of the closely watched Alzheimer’s drug Leqembi is off to a slow start. Still, demand for the treatment from Biogen and its Japanese partner Eisai is rising. That’s the update the two drugmakers gave Wall Street during their latest quarterly earnings calls earlier this month. But before we get into the numbers, […]
Read More